α₁-Adrenoceptors as potential therapeutic targets

Bibliography

• FANG Y, LAHIRI J, PICARD L: G-protein-coupled receptor microarrays for drug discovery. Drug Dis. Today (2003) 8(16):755–761.
   PubMedGoogle Scholar
• CHALMERS DT, BEHAN DP: The use of constitutively active GPCRs in drug discovery and functional genomics. Nat. Rev. Drug Dis. (2002) 1:599–608.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP: Adrenoceptor classification: an approach to improved cardiovascular therapeutics. Pharm. Acta. Helvet. (2000) 74:163–171.
   PubMedGoogle Scholar
• •Review on adrenoceptor classification and therapeutic challenges.
   Google Scholar
• MICHELOTTI GA, PRICE DT, SCHWINN DA: al-Adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther. (2000) 88:281–309.
   PubMed Web of Science ®Google Scholar
• ••Review on a1-ARs regulation at mRNAand protein levels.
   Google Scholar
• MIZOBE T, MAZE M, LAM V, SURYANARAYANA S, KOBILKA BK: Arrangement of transmembrane domains in adrenergic receptors. Similarity to bacteriorhodopsin. J. Biol. Chem. (1996) 271:2387–2389.
   PubMedGoogle Scholar
• SCHWINN DA, PAGE SO, MIDDLETON JP et al.: The a1c-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. Md. Pharmacol (1991) 40:619–626.
   Google Scholar
• GRAHAM RM, PEREZ DM, HWA J, PIASCIK MT: al-Adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ. Res. (1996) 78:737–749.
   Google Scholar
• TERZIC A. PUCEAT M, VASSORT G, VOGEL SM: Cardiac aracirenoceptors: an overview. PharmacoL Rev. (1993) 45:147–175.
   PubMedGoogle Scholar
• SIMPSON P, McGRATH A. SAVION S: Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ. Res. (1982) 51:787–801.
   PubMedGoogle Scholar
• SEI CA, IRONS CE, SPRENKLE AB et al.: The a-adrenergic stimulation of atrial natriuretic factor expression in cardiac myocytes requires calcium influx, protein kinase C, and calmodulin-regulated pathways. Biol. Chem. (1991) 266:15910–15916.
   Google Scholar
• YAMAZAKI T, KOMURO I, ZOU Y et al.: Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both al- and 13-adrenoceptors. Circulation (1997) 95:1260–1268.
   PubMedGoogle Scholar
• RAMIREZ MT, SAH VP, ZHAO XL et aL:The MEKK-JNK pathway is stimulated by ahadrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J. Biol. Chem. (1997) 272:28237–28346.
   PubMedGoogle Scholar
• ZECHNER D, THUERAUF DJ, HANFORD DS et aL: A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J. Cell Biol. (1997) 139:115–127.
   PubMed Web of Science ®Google Scholar
• McWHINNEY C, WENHAM D, KANWAL S et al.: Constitutively active mutants of the aia- and the alb-adrenergic receptor subtypes reveal coupling to different signaling pathways and physiological responses in rat cardiac myocytes. j Biol. Chem. (2000) 275:2087–2097.
   PubMed Web of Science ®Google Scholar
• SAH VP, HOSHIJIMA M, CHIEN KR et aL: Rho is required for Goal and aradrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J. Biol. Chem. (1996) 271:31185–31190.
   Google Scholar
• LI K, HE H, LI C, SIROIS P, ROVLEAU JL: Myocardial al-adrenoceptors inotropic effect and physiologic and pathologic implications. Life Sci. (1997) 60(16):1305–1318.
   PubMedGoogle Scholar
• SCHWINN DA, PRICE RR. Molecular pharmacology of human aradrenergic receptors: unique features of the a-a-subtype. Eur. UroL (1999) 36\(Supp1.1):7–10.
   Google Scholar
• AKHTER SA, LUTTRELL LM, ROCKMAN HA et al.: Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science (1998) 280:574–577.
   PubMed Web of Science ®Google Scholar
• PIASCIK MT, PEREZ DM: al-Acirenergic receptors: new insights and directions. PharmacoL Expt. Ther. (2001) 298:403–410.
   PubMed Web of Science ®Google Scholar
• •Review on aradrenergic receptors signalling and physiological functions.
   Google Scholar
• GARCIA-SAINZ JA, VAZQUEZ-PRADO J, VILLALOBOS-MOLINA R: al-Adrenoceptors: subtypes, signalling and roles in health and disease. Arch. Med. Res. (1999) 30:449–458.
   PubMed Web of Science ®Google Scholar
• BYLUND DB, EIKENBERG DC, HIEBLE JP et aL: IV International Union of Pharmacology nomenclature of adrenoceptors. PharmacoL Rev. (1994) 46:121–136.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, BYLUND DB, CLARKE DE et aL: International Union of Pharmacology. X . Recommendation for nomenclature of aradrenoceptors: consensus update. PharmacoL Rev. (1995) 47:267–270.
   Google Scholar
• MICHEL MC, KENNY B, SCHWINN DA: Classification of al adrenoceptor subtypes. Naunyn Schmiedebergs Arch. PharmacoL (1995) 352:1–10.
   PubMed Web of Science ®Google Scholar
• ZHONG H, MINNEMANN KP: al-adrenceptors subtypes. Eur. Pharmacol. (1999) 375:261–276.
   PubMed Web of Science ®Google Scholar
• MARUYAMA K, FUKUTOMI J, CHIBA T et aL: Two distinct aradrenoceptor subtypes in the human prostate: assessment by radioligand binding assay using 3H-prazosin. Gen. PharmacoL (1996) 27 (8): 1377–1381.
   PubMedGoogle Scholar
• ••Pivotal study demonstrating the presenceof high and low affinity isoforms of aiA-AR in human prostate.
   Google Scholar
• MARUYAMA K, NAKAMURA T, YOSHIHARA T et aL: Tamsulosin: assessment of affinity of 3H-prazosin bindings to two aradrenoceptor subtypes (am and all) in bovine prostate and rat heart and brain. Gen. PharmacoL (1998) 31(4):597–600.
   PubMedGoogle Scholar
• FORD AP, DANIELS DV, CHANG DJ et aL: Pharmacological pleiotropism of the human recombinant al,-adrenocepton implications for al-adrenoceptor classification. Br. J. PharmacoL (1997) 121:1127–1135.
   PubMed Web of Science ®Google Scholar
• HIRASAWA A, SHIBATA K, HORIE K et aL: Cloning, functional expression and tissue distribution of human a1c-acirenoceptor splice variants. FEBS Lett. (1995) 363:256–260.
   PubMed Web of Science ®Google Scholar
• CHANG D, CHANG T, YAMANISHI S. et aL: Molecular cloning, genomic characterization and expression of novel human ar,a-adrenoceptor isoforms. FEBS Lett. (1998) 422:279–283.
   Google Scholar
• RAZIK MA, LEEK, PRICER et aL: Transcriptional regulation of the human a1a-adrenergic receptor gene: characterization of the 5'-regulatory and promoter region./ Biol. Chem. (1997):28237–28346.
   Google Scholar
• RAMSAY D, CARR IC, PEDIANI J: High-affinity interactions between human aiKadrenoceptor C-terminal splice variants produce homo- and hetero dimers but do not generate the aiL-adrenoceptor. MoL PharmacoL (2004) 66(2):228–239.
   PubMedGoogle Scholar
• UBERTI MA, HALL RA, MINNEMAN KP: Subtype-specific dimerization of al-adrenoceptors: effect on receptor expression and pharmacological properties. MoL PharmacoL (2003) 64(6):1379–1390.
   PubMedGoogle Scholar
• MILLIGAN G, PEDIANI J, FIDOCK M, LOPEZ-GIMENEZ JF: Dimerization of aradrenoceptors. Biochem. Soc. Trans. (2004) 32(5):847–850.
   PubMedGoogle Scholar
• COGE F, GUENIN SP, RENOUARD -TRY A et aL: Truncated isoforms inhibit [3F1] prazosin binding and cellular trafficking of native human aiKadrenocetors. Biochem. J. (1999) 343:231–239.
   PubMedGoogle Scholar
• PRICE D, CHART R, BERKOWITZ D et aL: Expression of al-adrenergic receptor subtype mRNAs in rat tissues and human SK-N-MC neuronal cells: implications for aradrenergic subtype classification. MoL PharmacoL (1994) 45:171–175.
   PubMed Web of Science ®Google Scholar
• SCHWINN DA: Novel role for aradrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. (2000) 86\(Supp1.2):11–22.
   Google Scholar
• ••Review focusing on roles of (11-ARs inpathophysiology of BPH and LUTS.
   Google Scholar
• RUDNER XL, BERKOWITZ DE, BOOTH JV et al.: Subtype specific regulation of human vascular al adrenergic receptors by vessel bed and age. Circulation (1999) 100:2336–2343.
   PubMed Web of Science ®Google Scholar
• GOETZ AS, LUTZ MW, RIMELE TJ, SAUSSY DL Jr: Characterization of al adrenoceptor subtypes in human and canine prostate membranes. J. PharmacoL Exp. Ther. (1994) 119:797–803.
   Google Scholar
• NASU K, MORIYAMA N, KAWABE K et al.: Quantification and distribution of aradrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br. J. PharmacoL (1996) 119:797–803.
   PubMed Web of Science ®Google Scholar
• MURAMATSU I, OSHITA M, OHMURA T et al.: Pharmacological characterization of al-adrenoceptor subtypes in the human prostate; functional and binding studies. Br. J. UroL (1994) 74:331–335.
   Google Scholar
• MALLOY BJ, PRICE DT, PRICE RR et al.: al-Adrenergic receptor subtypes in human detrusor. j UroL (1998) 160:937–943.
   PubMed Web of Science ®Google Scholar
• MICHAEL MC, SCHAFERS RF, GOEPEL M: a-Blockers and lower urinary tract function: more than smooth muscle relaxation? BJU Int. (2000) 86\(Supp1.2):23–30.
   Google Scholar
• SCHWINN DA, MICHELOTTI GA: al-Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the aid subtype in filling symptoms and effects of aging on vascular expression. BJU Int. (2000) 85\(Supp1.2):6–11.
   Google Scholar
• PERLBERG S, CAINE M: Adrenergic response of bladder muscle in prostatic obstruction. Urol. (1982) 20:524–527.
   PubMed Web of Science ®Google Scholar
• RESTORICK JM, MUNDY AR: The density of cholinergic and a and 13 receptors in the normal and hyperreflexic human detrusor. Br. J. UroL (1989) 63:32–35.
   PubMedGoogle Scholar
• ANDERSSON KE: a-Aclrenoceptors and benign prostatic hyperplasia: basic principles for treatment with a-adrenoceptor antagonists. World J. Urol. (2002) 19:390–396.
   Web of Science ®Google Scholar
• LOWE FC: Role of newer al-adrenergic receptor antagonists in the treatment of benign prostatic hyperplasia related lower urinary tract symptoms. Clin. Ther. (2004) 26:1701–1713.
   PubMed Web of Science ®Google Scholar
• KELLUM JA, PINSKY MR: Use of vasopressor agents in critically ill patients. Curr. Opin. Crit. Care (2002) 138:145–155.
   Google Scholar
• PANG CC: Autonomic control of the nervous system in health and disease: effects of drugs. PharmacoL Ther (2001) 90(2-3):179–230.
   PubMed Web of Science ®Google Scholar
• ROMEO G, MATERIAL, SALERNO L et al.: Novel antagonists for aradrenoceptor subtypes. Expert Opin. Ther. Patents (2004) 14(5):619–637.
   Google Scholar
• WILLEMS EW, VALDIVIA LF, VILLALON CM, SAXENA PR: Possible role of a-adrenoceptor subtypes in acute migraine therapy. Cepha/a/gia (2003) 23(4):245–257.
   PubMedGoogle Scholar
• ROWLEY TJ, DANIEL D, FLOOD P: The role of adrenergic and cholinergic transmission in volatile anesthetic-induced pain enhancement. Anesthesia Analgesia. (2005) 100(4):991–995.
   PubMedGoogle Scholar
• DE GROAT WC, YOSHIMURA N: Pharmacology of the lower urinary tract. Ann. Rev. PharmacoL ToxicoL (2001) 41:691–721.
   PubMed Web of Science ®Google Scholar
• TESTA R, GUARNERI L, IBBA M et al.: Characterization of aradrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur. j PharmacoL (1993) 249:307–315.
   PubMedGoogle Scholar
• SULLIVAN J, ABRAMS P: Pharmacological management of incontinence. Eur. UroL (1999) 36\(Suppl. 1):89–95.
   Google Scholar
• BUCKNER SA, MILICIC I, DAZA AV et al.: ABT-866, a novel alicadrenoceptor agonist with antagonist properties at the all,- and am-adrenoceptor subtypes. Eur. PharmacoL (2002) 449:159–165.
   PubMedGoogle Scholar
• ALTENBACH RJ, KHILEVICH A, MERJER MD et aL: 1\143-(1H-imiclazol-4-yl-methyl)phenyilethanesulfonamide (ABT-866, 1),(1) a novel aradrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J. Med. Chem. (2002) 45(20):4395–4397.
   PubMedGoogle Scholar
• IMS Chemical Pioneer 2004. IMS WorldPublications Ltd.
   Google Scholar
• BLUE DR, DANIELS DV GEVER JR et al.: Pharmacological characteristics of Ro 115–1240, a selective Ulm,adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. BJU Int. (2004) 93(1):162–170.
   Google Scholar
• MUSSELMAN DM, FORD AP, GENNEVOIS DJ: A randomized crossover study to evaluate Ro 115-1240, a selective alm,-adrenoceptor partial agonist in women with stress urinary incontinence. BJU Int. (2004) 93(1):78–93.
   PubMed Web of Science ®Google Scholar
• ALHASSO A, GLAZENER CMA, PICKARD R, N'DOW J: Adrenergic drugs for urinary incontinence in adults. (Cochrane Review). Cochrane Database Syst. Rev. (2005) 20(3):CD 001842.
   Google Scholar
• VARMA DR, DENG XF: Cardiovascularal-adrenoceptor subtypes: functions and signaling (Review). Can. J. Physiol. PharmacoL (2000) 78:267–292.
   PubMedGoogle Scholar
• CHALOTHORN D, MCCUNE DF, EDELMANN SE et al.: Differential cardiovascular regulatory activities of the a,- and am-adrenoceptor subtypes. PharmacoL Exp. Ther. (2003) 305:1045–1053.
   PubMedGoogle Scholar
• VECCHIONE C, FRATTA L, RIZZONI D et al.: Cardiovascular influences of alb-adrenergic receptor defect in mice. Circulation (2002) 105:1700–1707.
   PubMed Web of Science ®Google Scholar
• HOSODA C, KOSHIMIZU TA, TANOUE A et al.: Two aradrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. MoL PharmacoL (2005) 67(3):912–922.
   PubMedGoogle Scholar
• TANOUE A. NASA Y, KOSHIMIZU T et al.: The am-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J. Clin. Invest. (2002) 109:765–775.
   Google Scholar
• RUSSEL C-W.: The use of a-adrenoceptorantagonists in lower urinary tract disease. Expert. Opin. Pharmacother. ( 2002) 3:167–172.
   PubMedGoogle Scholar
• MO1 1ET N, BRESSOLLE F, DELMAS ROBERT M, COSTA P: Prostatic tissual distribution of alfitzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur. UroL (2003) 44:101–105.
   PubMedGoogle Scholar
• MARTIN DJ, LLUEL P, POUYET T et al.: Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci. (1998) 63(3):169–176.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, BUCKNER SA, BOUNE ME: Preclinical pharmacology of Fiduxosin, a novel al-adrenoceptor antagonist with uroselective properties. J. PharmacoL Exp. Ther. (2002) 200(2):478–486.
   Google Scholar
• MICHEL MC: Ejaculatory dysfunction and a-adrenoceptor antagonists. BJU Int. (2004) 94:443–448.
   PubMedGoogle Scholar
• FORRAY C, NOBLE SA Subtype selective aradrenoceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opin. Investig. Drugs (1999) 8:2073–2094
   PubMedGoogle Scholar
• DE MARINIS RNI, WISE M, HIEBLE JP et al.: The a,Adrenergic Receptor. Ruffolo RR Jr (Ed.), Humana Press, Clifton, NJ, USA (1987):211–265.
   Google Scholar
• MEYER MD, ALTENBACH RJ, BASHA FZ et al.: Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz [e] isoindole a IA adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH). J. Med. Chem. (2000) 43:1586–1603.
   PubMed Web of Science ®Google Scholar
• MEYER MD, ALTENBACH RJ, BAT H et al.: Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz [e] isoindole a 1A-adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH). J. Med. Chem. (2001) 44:1971–1985.
   PubMedGoogle Scholar
• HAIGHT AR, BAILEY AE, BAKER WS et al.: A scalable synthesis of fiduxosin. Organic Proc. Res. Dev. (2004) 8:897–902.
   Google Scholar
• KHATUYA H, HUTCHINGS RH, KUO G-H et al.: Aryl piperazine substituted heterocycles as selective ala adrenergic antagonists. Bioorg. Med. Chem. Lett. (2002) 12:2443–2446.
   PubMedGoogle Scholar
• KHATUYA H, PULITO JOLLIFFE LK, LI X, MURRAY WV: Novel thiophene derivatives for the treatment of benign prostatic hyperplasia. Bioorg. Med. Chem. Lett. (2002) 12:2145–2148.
   PubMedGoogle Scholar
• PATANE E, Pf1"1AL V GUERRERA F et al: Synthesis of 3-arylpiperzinylalkylpyrrolo [3,2-d]pyrimidine-2,4-dione derivatives as novel, potent and selective al-adrenoceptor ligands. J. Med. Chem (2005) 48:2420–2431.
   PubMedGoogle Scholar
• LOPEZ FJ, ARIAS L, CT-JAN R et al.: Synthesis, pharmacology and pharmacokinetics of 3-(4-aryl-piperazin-1-yl-alkyOuracils as uroselective a1A-antagonists. Bioorg. Med. Chem. Lett. (2003) 13:1873–1878.
   PubMedGoogle Scholar
• LEONARDI A. BARLOCCO D, MONTESANO F et al.: Synthesis, screening and molecular modeling of new, potent and selective antagonists at the a1-adrenergic receptor. J. Med. Chem. (2004) 47:1900–1918.
   Google Scholar
• KONKEL MJ, WETZEL JM, CAHIR M, CRAIG DA, NOBLE SA: Synthesis and structure-activity relationships of fluoro analogues of 8-12- [4-(4- methoxyphenyl ) piperazin-1-yl] ethy11-8-azaspiro [4.5] dodecane-7,9-dione as selective a1-adrenergic receptor antagonists./ Med. Chem. (2005) 48:3076–3079.
   Google Scholar
• ••This paper describes am-AR antagonistswith improved profile over BMY-7378.
   Google Scholar
• HEINRICH T, BURSCHKA C, WARNECK J, TACKE R: Synthesis and pharmacological properties of silicon-containing 1,4-dihydropyridine derivatives: calcium channel antagonists and aradrenoceptor antagonists of the sila-niguldipine type. Organometallics (2004) 23:361–366.
   Web of Science ®Google Scholar
• •This paper describes silicon based (11-AR antagonists for the treatment of BPH.
   Google Scholar
• QUAGLIAW, PIGINI M, PIERGENTILI A et al.: Structure-activity relationships in 1,4-benzodioxan related compounds. 7. Selectivity of 4-phenylchroman analogues for aradrenoceptor subtypes. J. Med. Chem. (2002) 45:1633–1643.
   Google Scholar
• BRASILI L, SORBI C, FRANCHINI S et al.: 1,3-Dioxolane based ligands as a novel class of aradrenoceptor antagonists. J. Med. Chem. (2003) 46:1504–1511.
   PubMedGoogle Scholar
• BOLCHI C, CATALANO P, FUMAGALLI L, GROENEWOUD KM, YATES BF: Structure-activity studies for a novel series of homochiral naphtha and tetrahydronaphtho analogues of al-antagonist WB-4101. Bioorg. Med. Chem. (2004) 12:4937–4951.
   PubMed Web of Science ®Google Scholar
• BREMNER JB, COBAN B, GRIFFITH R, GROENEWOUD KM, YATES BF: Ligand design for aradrenoceptor subtype selective antagonists. Bioorg. Med. Chem. (2000) 8:201–214.
   PubMed Web of Science ®Google Scholar
• BREMNER JB, COBAN B, GRIFFITH R: Pharmacophore development for antagonists at aradrenergic receptor subtypes. J. Comp. Aided Mol Des. (1996) 10:545–577.
   PubMed Web of Science ®Google Scholar
• GIARDIN D, CRUCIANELLI M, ROMANELLI R, LEONARDI A, POGGESI E, MELCHIORRE C: Synthesis and biological profile of the enatiomers of [4-(4-amino-6,7-dimethoxyquinazolin-2-y1)-as-octahydro-quinoxilin-1-y1]-furan-2-ylmethanone( cyclazosin), a potent competitive am-adrenoceptor antagonist. J. Med. Chem. (1996) 39:4602–4607.
   PubMedGoogle Scholar
• PATANE MA, SCOTT AL, BROTEN TP et al.: 4-Amino-244- kbenzyloxycarbony1)-2(S)- [[(1,1-(dimethylethypamino]carbony1]-piperaziny1]-6,7-dimethoxyquinazoline (L-765,314): a potent and selective am adrenergic receptor antagonists. J. Med. Chem. (1998) 41:1205–1208.
   PubMed Web of Science ®Google Scholar
• MINARINI A, BUDRIESI R, CHIARINI A, LEONARDI A. MELCHIORRE C: Search for aradrenoceptor subtypes selective antagonists: design, synthesis and biological activity of cystazosin, an am-adrenoceptor antagonist. Bioorg. Med. Chem. Lett. (1998) 8:1353–1358.
   PubMed Web of Science ®Google Scholar
• SAGRATINI G, BUCCIONI M, GULINI U et al.: (+)-Cyclazosin derivatives as aradrenoceptor antagonists. Med. Chem. Res. (2004) 13:190–199.
   Web of Science ®Google Scholar
• ANTONELLO A. HRELIA P, LEONARDI A et al.: Design, synthesis and biological evaluation of prazosin-related derivatives as multipotent compounds. J. Med. Chem. (2005) 48:28–31.
   Google Scholar
• CONNOLY TJ, MATCHETT M, SARNIA K: Process development and scale-up of a selective aradrenoceptor antagonist. Org. Proc. Res. Dev. (2005) 9:80–87.
   Google Scholar
• CHUEH S-C, CHERN J-W, CHOONG C-M, GUH J-H, TENG C-M: Characterization of some novel al-adrenoceptor antagonists in human hyperplastic prostate. Eur. J. Pharmacol (2002) 445:125–131.
   PubMedGoogle Scholar
• •This paper describes quinazoline-based compounds with selectivity for am-AR over am-AR.
   Google Scholar
• INDRA B, MATSUNAGA K, HOSHINO 0, SUZUKI M, OGASAWARA H, OHIZUMI Y: Structure-activity relationship studies with (±)-nantenine derivatives for al-adrenoceptor antagonist activity. Eur. Pharmcol. (2002) 437:173–178.
   PubMedGoogle Scholar
• DEBRUYNE F, BOYLE P, CALAIS DA SILVA F et al.: Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERNIAL study subset analysis. Eur. Urol. (2004) 45:773–780.
   Google Scholar
• SHARPE IA, THOMAS L, LOUGHNAN M et al.: Allosteric a-adrenoceptor antagonism by the conopeptide p-TIA. j Biol. Chem (2003) 278:34451–34457.
   PubMedGoogle Scholar
• McCONNEL JD, ROEHRBORN CG, BAUTISTA et al.: The long term effects of doxazosin, finasteride and combination therapy on the clinical progression of BPH. N Engl. J. Med. (2003) 349:2387–2398.
   PubMedGoogle Scholar
• CAMPBELL SF, HARDSTONE JD, PALMER MJ: 2,4-Diamino-6,7-dimethoxyquinoline derivatives as aradrenoceptor antagonists and antihypertensive agents. J. Med. Chem. (1988) 31:1031–1035.
   PubMed Web of Science ®Google Scholar